Topic

Articles

With a complicated and challenging global picture greeting the new year, driven by the continuing pandemic and historic political and regulatory changes in the US and Europe, we outline eight diverse trends critical to biopharma’s future health and growth.

2021 in Focus: Pharm Exec’s Annual Industry Outlook

Julian Upton is Pharmaceutical Executive’s European and Online Editor. He can be reached at 

Pharm Exec Hits 40 

Donna L. LaVoie outlines the takeaways of a recent industry webinar discussing global trends on public and private markets, JPM virtual week, and more. 

2021 Preview: A 360-Degree Global Market View

Professor Guido Palazzo is Academic Director at Executive Education HEC.

If the COVID-19 crisis represents an unprecedented opportunity for pharma to strengthen its public reputation, it also poses enormous risks if things go wrong, writes Professor Guido Palazzo.

Why Culture, Ethics, and Compliance Are More Important Than Ever Post-COVID

Gina Parry, National Account Manager, VAI

If telehealth is here to stay, how is the industry adjusting?

Keeping Up with Telehealth: Pharma’s Evolution 

A brief look into how the Gene Editing Institute researching the diversity of responses in African-American regenerative cells to various forms of CRISPR.

CRISPR for Diversity, and Humanity’s, Sake

Beth Doladee, M.A., M.B.A. and Neelima Paranjpey, Ph.D, are Managing Consultants at Vaya Group.

To effectively lead in today’s unpredictable environment, several major pharma companies are turning to a neuroscience-based learning approach to leadership development.

Supporting Successful Pharma Leadership with Neuroscience-Based Learning

Dr. George Westerman talks to Michael Wong about how smarter executives will successfully lead their workforces in a post COVID-19 business environment.

Planning Ahead for a Post COVID-19 Workforce and Workplace

Jill Wechsler is Pharm Exec's Washington Corespondent

President Trump has taken on the pharma industry in a surprise move making significant cuts in reimbursement for drugs covered by Medicare. 

Trump Escalates Drug Pricing War

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Industry Trends